









Markets
/
Stocks
/
nasdaq-abvc
/

ABVC Biopharma Inc

ABVC

2.820USD

-0.070-2.43%

Market hours （ET）Quotes delayed by 15 min

68.21MMarket Cap

LossP/E TTM



ABVC Biopharma Inc

2.820

-0.070-2.43%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ABVC Biopharma Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ABVC Biopharma Inc's Score

Industry at a Glance

Industry Ranking

224 / 407

Overall Ranking

461 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ABVC Biopharma Inc Highlights

StrengthsRisks

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.

Growing

The company is in a growing phase, with the latest annual income totaling USD 509.59K.

Undervalued

The company’s latest PE is -10.31, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 367.48K shares, decreasing 51.76% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 111.53K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.75, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 795.95K, representing a year-over-year increase of 104.47%, while its net profit experienced a year-over-year increase of 568.15%.

Score

Industry at a Glance

Previous score

5.75

Change



Financials

5.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.44

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

ABVC Biopharma Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.89, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -10.31, which is -97.79% below the recent high of -0.23 and -80.35% above the recent low of -18.59.

Score

Industry at a Glance

Previous score

6.89

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 224/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.95, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 3.23 and the support level at 2.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.84

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Sell

RSI(14)

48.511

Neutral

STOCH(KDJ)(9,3,3)

40.481

Neutral

ATR(14)

0.160

High Vlolatility

CCI(14)

-2.387

Neutral

Williams %R

56.250

Sell

TRIX(12,20)

-0.227

Sell

StochRSI(14)

65.526

Neutral

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.858

Sell

MA10

2.876

Sell

MA20

2.926

Sell

MA50

2.922

Sell

MA100

2.946

Sell

MA200

1.938

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 1.56%, representing a quarter-over-quarter decrease of 91.69%. The largest institutional shareholder is The Vanguard, holding a total of 111.53K shares, representing 0.47% of shares outstanding, with 30.96% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Jiang (Shuling)

1.00M

+3.82%

YuanGene, Corp

829.70K

Jiang (Tsung-Shann)

375.99K

-11.15%

Jiang (Eugene)

131.16K

The Vanguard Group, Inc.

Star Investors

111.53K

+137.57%

Geode Capital Management, L.L.C.

110.50K

+5.76%

Patil (Uttam)

72.43K

Odaira (Yoshinobu)

57.76K

XTX Markets LLC

52.63K

-12.93%

Jiang (Chang-Jen)

42.03K

-0.12%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.35, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.